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Angiographic Stent Thrombosis After
Routine Use of Drug-Eluting Stents in
ST-Segment Elevation Myocardial Infarction
The Importance of Thrombus Burden
Georgios Sianos, MD, PHD, Michail I. Papafaklis, MD, Joost Daemen, MD, Sofia Vaina, MD,
Carlos A. van Mieghem, MD, Ron T. van Domburg, PHD, Lampros K. Michalis, MD, MRCP,
Patrick W. Serruys, MD, PHD, FACC
Rotterdam, the Netherlands
Objectives This study sought to investigate the impact of thrombus burden on the clinical outcome and angiographic
infarct-related artery stent thrombosis (IRA-ST) in patients routinely treated with drug-eluting stent (DES) implan-
tation for ST-segment elevation myocardial infarction (STEMI).
Background There are limited data for the safety and effectiveness of DES in STEMI.
Methods We retrospectively analyzed 812 consecutive patients treated with DES implantation for STEMI. Intracoronary
thrombus burden was angiographically estimated and categorized as large thrombus burden (LTB), defined as
thrombus burden 2 vessel diameters, and small thrombus burden (STB) to predict clinical outcomes. Major
adverse cardiac events (MACE) were defined as death, repeat myocardial infarction, and IRA reintervention.
Results Mean duration of follow-up was 18.2  7.8 months. Large thrombus burden was an independent predictor of
mortality (hazard ratio [HR] 1.76, p  0.023) and MACE (HR 1.88, p  0.001). The cumulative angiographic
IRA-ST was 1.1% at 30 days and 3.2% at 2 years, and continued to augment beyond 2 years. It was significantly
higher in the LTB compared with the STB group (8.2% vs. 1.3% at 2 years, respectively, p  0.001). Significant
independent predictors for IRA-ST were LTB (HR 8.73, p  0.001), stent thrombosis at presentation (HR 6.24, p
 0.001), bifurcation stenting (HR 4.06, p  0.002), age (HR 0.55, p  0.003), and rheolytic thrombectomy (HR
0.11, p  0.03).
Conclusions Large thrombus burden is an independent predictor of MACE and IRA-ST in patients treated with DES for
STEMI. (J Am Coll Cardiol 2007;50:573–83) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.059t
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Primary percutaneous coronary intervention
(PCI) with bare metal stent (BMS) implanta-
tion is established as the treatment of choice for
ST-segment elevation myocardial infarction
(STEMI) (1,2). There are limited data regard-
ing the use of drug-eluting stents (DES) in a
TEMI setting. Initial small registries showed superiority
f sirolimus-eluting stents (SES) compared with BMS up to
year of follow-up (3–8). Two randomized trials confirmed
hese results (9,10). The findings regarding paclitaxel-
luting stents (PES) are less clear with positive small
ingle-center reports (11,12), but a negative randomized
rom the Erasmus Medical Center, Department of Interventional Cardiology,
horaxcenter, Rotterdam, the Netherlands.c
Manuscript received December 12, 2006; revised manuscript received March 26,
007, accepted April 10, 2007.rial (13). There are no data on the routine use of DES for
TEMI with midterm outcomes.
The etiology of stent thrombosis is multifactorial,
nvolving stent thrombogenicity and procedure-, lesion-,
nd patient-related factors (14). Acute coronary syn-
romes have been recognized as a factor of increased rates
f stent thrombosis both for BMS (15–17) and DES
18–20). Limited data exist regarding the incidence
nd predictors of DES thrombosis during STEMI
9,10,13,18).
In patients with acute coronary syndromes, angiographic
resence of thrombus increases the incidence of in-hospital
ajor adverse cardiac events (MACE) (21,22). Mechanical
reatment of thrombotic lesions, by means of thrombectomy
nd distal protection devices, has been proposed to prevent the
omplications caused by thrombus and improve clinical out-
omes, but randomized trials failed to show any beneficial
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on myocardial reperfusion or clin-
ical outcome during STEMI
(23,24). There is no angiographic
thrombus classification validated
to predict clinical outcomes.
In a large unselected cohort of
consecutive patients with STEMI
treated with PCI and DES, we
propose a simple angiographic
thrombus classification, and we re-
port the 2-year clinical outcome
and incidence and predictors of
infarct-related artery stent throm-
bosis (IRA-ST).
Patients and Methods
Patients and procedure. From
April 2002, when DES were in-
troduced, until December 2004,
900 consecutive patients pre-
sented with STEMI and under-
went PCI (primary or rescue)
within 12 h after the onset of
chest pain; 37 (4.1%) were
treated with balloon angioplasty,
51 (5.7%) with BMS, and 812
(90.2%) with DES. The BMS
were implanted because of un-
availability of all DES sizes
(length or diameter) in the ini-
tial period of their approval.
his analysis focuses on patients treated exclusively with
ES. All patients were pretreated with 250 mg aspirin
nd 300 mg clopidogrel. Preprocedural intracoronary
itrates were systematically administered. A PCI was
erformed according to standard clinical practice. The
se of rheolytic thrombectomy (RT) (Possis Medical,
nc., Minneapolis, Minnesota), the only thrombectomy
r aspiration system used, and periprocedural pharmaco-
ogical treatment (e.g., glycoprotein IIb/IIIa antagonists)
ere at the operator’s discretion. All patients received
ual antiplatelet therapy: aspirin 325 mg/day indefinitely
nd clopidogrel 75 mg/day for 3 and 6 months after SES
nd PES implantation, respectively.
linical follow-up. Information regarding baseline clinical
haracteristics, procedural details, and in-hospital events
as obtained from electronic databases maintained at Eras-
us Medical Center. Postdischarge survival status was
btained from the Municipal Civil Registry. A question-
aire was mailed to all living patients focusing on rehospi-
alization and MACE. Referring cardiologists, general
ractitioners, and patients were contacted when necessary
or additional information. All patients provided written
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
IRA-ST  infarct-related
artery stent thrombosis
LTB  large thrombus
burden
MACE  major adverse
cardiac events
MI  myocardial infarction
PES  paclitaxel-eluting
stents
PCI  percutaneous
coronary intervention
RT  rheolytic
thrombectomy
SES  sirolimus-eluting
stent(s)
STB  small thrombus
burden
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombosis In
Myocardial Infarction
TLR  target lesion
revascularization (of the
infarct-related artery)
TVR  target vessel
revascularization (of the
infarct-related artery)nformed consent. cngiographic analysis. Intracoronary thrombus was an-
iographically identified and scored in 5 grades as previously
escribed (25). According to this classification, in thrombus
rade 0 (G0), no cineangiographic characteristics of throm-
us are present; in thrombus grade 1 (G1), possible throm-
us is present, with such angiography characteristics as
educed contrast density, haziness, irregular lesion contour,
r a smooth convex meniscus at the site of total occlusion
uggestive but not diagnostic of thrombus; in thrombus
rade 2 (G2), there is definite thrombus, with greatest
imensions 1/2 the vessel diameter; in thrombus grade 3
G3), there is definite thrombus but with greatest linear
imension 1/2 but 2 vessel diameters; in thrombus
rade 4 (G4), there is definite thrombus, with the largest
imension 2 vessel diameters; and in thrombus grade 5
G5), there is total occlusion (unable to assess thrombus
urden due to total vessel occlusion).
In patients presenting with an open IRA, thrombus was
cored in the preintervention angiographic sequence more
learly depicting its size. In patients presenting with an
ccluded IRA (G5; essentially no flow and not thrombus
lassification), thrombus was reclassified into one of the
ther categories after flow achievement with either guide-
ire crossing or a small (diameter 1.5 mm) deflated balloon
assage or dilation. After reclassification of the G5 group,
hrombus burden was stratified in 2 categories, scored as a
mall thrombus burden (STB) for thrombus G4 and a
arge thrombus burden (LTB) for thrombus G4, based on
linical outcomes.
Thrombosis In Myocardial Infarction (TIMI) flow and
yocardial blush were assessed as previously reported
26,27). No reflow was defined as reduced antegrade flow
TIMI flow grade 2) in the absence of occlusion at the
reatment site or evidence of distal embolization. Distal
mbolization was defined as migration of a filling defect to
istally occlude the infarct-related vessel or one of its
ranches, or a new abrupt cutoff of the distal vessel/branch.
Stent thrombosis was defined as a complete or partial
cclusion within the stented segment with evidence of
hrombus and reduced antegrade flow (TIMI flow grade
3) with a concurrent acute clinical ischemic event.
he stent thrombosis cases were categorized according to the
iming of occurrence into acute (from the end of the procedure
p to 24 h), subacute (from 24 h up to 30 days), late
between 30 days and 6 months), and very late (6
onths).
All procedural parameters, including thrombus classifica-
ion, were assessed by 2 experienced interventional cardiol-
gists reviewing the angiograms together. Both reviewers
ere blinded to clinical outcomes. Consensus was achieved
n all patients. Half of the films were randomly selected and
eanalyzed by the same analysts for intraobserver variability,
nd by a third experienced interventional cardiologist for
nterobserver variability of the proposed LTB and STB
lassification.
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August 14, 2007:573–83 DES Thrombosis and Thrombus Burden in STEMIefinitions. Repeat myocardial infarction (MI) (nonfatal)
as defined as new clinical symptoms or electrocardiogram
hanges associated with an increase in the creatine kinase
evel to more than twice the upper normal limit with an
ncreased creatine kinase-MB. In cases in which the creatine
inase level had not returned to normal values after the
ndex event, a second peak was defined as repeat MI. Target
esion revascularization (TLR) was defined as any repeat
evascularization of the IRA involving the stent and/or its
-mm proximal or distal edges.
Target vessel revascularization (TVR) was defined as any
epeat revascularization of the IRA. A MACE was defined
s death, repeat MI, and TVR.
tatistics. Categorical variables (presented as counts and
ercentages) were compared using the chi-square test or
isher exact test where the expected value in any cell was
aseline Clinical, Angiographic, and Procedural Characteristics
Table 1 Baseline Clinical, Angiographic, and Procedural Charac
Characteristic Total Population (n  792)
Age (yrs) 59.4 11.5
Female 166 (21%)
Diabetes 80 (10.1%)
Hypertension 215 (27.1%)
Hypercholesterolemia 240 (30.3%)
Smoking 299 (37.8%)
Family history of CAD 207 (26.1%)
Previous MI 80 (10.1%)
Previous PCI 46 (5.8%)
MI presentation
Infarct duration (h)† 4.5 11.3
Peak CK-MB (IU/l) 314.5 303.6
Primary PCI 712 (89.9%)
Rescue PCI 80 (10.1%)
Cardiogenic shock 76 (9.6%)
Stent thrombosis 22 (2.8%)
Prehospital resuscitation 21 (2.7%)
Multivessel disease 309 (39.0%)
Infarct-related artery
Left main stem 11 (1.4%)
Left anterior descending 404 (51%)
Right coronary artery 297 (37.5%)
Circumflex coronary artery 75 (9.5%)
Vein or IMA graft 5 (0.6%)
Multivessel PCI 85 (10.7%)
Pacemaker 107 (13.5%)
IABP 91 (11.5%)
Inotropes 90 (11.4%)
Glycoprotein IIb/IIIa antagonists 401 (50.6%)
Distal protection device 15 (1.9%)
Drug-eluting stent type
Sirolimus-eluting stent 200 (25.3%)
Paclitaxel-eluting stent 592 (74.7%)
Bifurcational stenting 51 (6.4%)
Direct stenting 442 (55.8%)
Rheolytic thrombectomy 63 (8.0%)
STB versus LTB group. †Infarct duration was available in 531 patients (361 in the STB and 170
CAD coronary artery disease; CK creatine kinase; IABP intra-aortic balloon pump; IMA internal
oronary intervention; STB  small thrombus burden.5. The unpaired t test was used for comparing continuous
ariables (presented as the mean  SD). Cumulative event
ates were estimated using the Kaplan-Meier method, and
ifferences between groups were assessed by the log-rank
est of significance. Variables associated with event rates on
nivariate analysis at a level of p  0.2 were entered in a
ultivariate Cox model with a stepping algorithm, and then
he variables referring to thrombus burden and RT were
orced into the model to estimate their independent effect
long with the other predictors of clinical outcome (mor-
ality, MACE, stent thrombosis). In-hospital events were
ncluded in the survival analysis. All tests were 2-tailed,
nd a value of p  0.05 was considered significant. The
PSS statistical software package (version 12.0 for Win-
ows, SPSS Inc. Chicago, Illinois) was used for the
nalysis.
tics
STB (n  567) LTB (n  225) p Value*
59.6 11.6 58.8 11.1 0.38
122 (21.5%) 44 (19.6%) 0.54
50 (8.8%) 30 (13.3%) 0.057
148 (26.1%) 67 (29.8%) 0.294
177 (31.2%) 63 (28.0%) 0.374
223 (39.3%) 76 (33.8%) 0.146
144 (25.4%) 63 (28.0%) 0.452
54 (9.5%) 26 (11.6%) 0.392
24 (4.2%) 22 (9.8%) 0.003
4.3 8.5 4.9 14.9 0.659
305.3 292.4 335.9 328.2 0.699
503 (88.7%) 209 (92.9%) 0.079
64 (11.3%) 16 (7.1%) 0.079
50 (8.8%) 26 (11.6%) 0.238
6 (1.1%) 16 (7.1%) 0.001
15 (2.6%) 6 (2.7%) 0.987
229 (40.4%) 80 (35.6%) 0.209
0.007
10 (1.8%) 1 (0.4%)
299 (52.7%) 105 (46.7%)
199 (35.1%) 98 (43.6%)
58 (10.2%) 17 (7.6%)
1 (0.2%) 4 (1.8%)
69 (12.2%) 16 (7.1%) 0.038
46 (8.1%) 61 (27.1%) 0.001
57 (10.1%) 34 (15.1%) 0.044
59 (10.4%) 31 (13.8%) 0.177
251 (44.3%) 150 (66.7%) 0.001
2 (0.4%) 13 (5.8%) 0.001
0.004
159 (28.0%) 41 (18.2%)
408 (72.0%) 184 (81.8%)
33 (5.8%) 18 (8.0%) 0.26
321 (56.6%) 121 (53.8%) 0.469
4 (0.7%) 59 (26.2%) 0.001
TB group).teris
in the L
mammary artery; LTB large thrombus burden; MImyocardial infarction; PCI percutaneous
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DES Thrombosis and Thrombus Burden in STEMI August 14, 2007:573–83Kappa statistics were calculated for estimating the in-
raobserver (kappa  0.95) and interobserver (kappa 
.91) variability of the proposed thrombus classification
fter selecting randomly and reanalyzing half of the films.
esults
omplete follow-up information was obtained in 798
98.3%) patients treated with DES (mean duration 18.2 
.8 months), and both clinical follow-up and thrombus
urden classification was available in 792 (97.5%) patients.
inimum follow-up for patients who survived the index
ospitalization was 12 months. Baseline demographic and
rocedural characteristics of the total population and ac-
ording to thrombus burden are presented in Table 1.
ngiographic classification of thrombus burden. Throm-
us burden grading is presented in Table 2. More than half
f the patients (57%) presented with an occluded IRA (G5).
eclassification into a thrombus category (G0 to G4) was
chieved in 449 (98.7%) patients; in 305 (67.9%) after some
ow achievement with guidewire crossing, and in 144
32.1%) after a deflated 1.5-mm balloon passage or dilation
mean dilation pressure was 6.8 atm and mean duration of
ilation was 16.6 s). An example of thrombus reclassifica-
ion after wire crossing is presented in Figure 1. In 2
atients, thrombus G5 was sustained (no flow achievement),
nd in 4 patients reclassification was not possible because of
nadequate angiographic documentation. Finally, thrombus
urden was estimated in 792 (99.2%) patients.
In the reclassified G5 group, there were more G4 patients
ompared with the group with open IRA (33.0% vs. 22.4%,
 0.001).
linical outcome. The 2-year cumulative clinical out-
omes of the total population are presented in Figure 2, and
-year cumulative mortality and MACE rate according to
hrombus score after G5 reclassification are depicted in
igures 3A and 3B. Patient groups G1, G2, and G3 had
imilar 2-year cumulative mortality (7.8% vs. 9.6% vs. 7.9%,
espectively, p  0.95) and MACE rates (15% vs. 13.8% vs.
lassification of Thrombus Burden
Table 2 Classification of Thrombus Burden
Thrombus Score
Thrombus Burden*
Reference
(n  798)
Reference
Non-G5†
(n  343)
G5
Reclassified†
(n  455)
Reclassified
Final
(n  798)
G5 455 (57.0) 0 (0) 2 (0.4) 2 (0.3)
G4 77 (9.6) 77 (22.4) 148 (32.5) 225 (28.2)
G3 61 (7.6) 61 (17.8) 80 (17.6) 141 (17.7)
G2 95 (11.9) 95 (27.7) 113 (24.8) 208 (26.1)
G1 68 (8.5) 68 (19.8) 87 (19.1) 155 (19.4)
G0 42 (5.3) 42 (12.2) 21 (4.6) 63 (7.9)
Not available‡ 0 (0) 0 (0) 4 (0.9) 4 (0.5)
ata are presented as n (%). *Reference is the classification that includes patients with occluded
essels at presentation (G5), and reclassified is the one after thrombus evaluation in this group
ollowing minimal intervention. †p  0.001 for the comparison of G0, G1, G2, G3, G4 between
Reference Non-G5” and “G5 Reclassified” groups. ‡In 4 patients, reclassification was not possible
ecause of inadequate angiographic documentation.2.8%, respectively, p  0.78), whereas groups G0 and G4
ad higher rates (mortality 14.6% and 13%, respectively, p
0.22; MACE rate 24.4% and 24.9%, respectively, p 
.001) compared with the former groups. The G0 group
ompared with G1 to G3 had more multivessel PCI (20.6%
s. 11.1%, p 0.029) and more left main stem and less right
oronary artery involvement (4.8% vs. 1.4% and 19% vs.
7.1%, respectively, p  0.001).
Based on the aforementioned results, we stratified throm-
us burden in 2 groups of patients with STB, combining
Figure 1 Thrombus Burden Evaluation in a Patient
Presenting With an Occluded Infarct-Related Artery
(A) An occluded left anterior descending coronary artery (arrow) after the take-
off of the first diagonal branch (D1) in a patient who presented with anterior
myocardial infarction. (B) After crossing the occlusion with an angioplasty
guidewire (arrowheads) and without further intervention, Thrombolysis In Myo-
cardial Infarction flow grade 1 was restored, allowing the visualization of a
large thrombus (arrows).
Figure 2 Overall Clinical Outcomes
Two-year cumulative mortality, repeat nonfatal myocardial infarction (MI),
infarct-related artery lesion repeat revascularization (TLR), infarct-related artery
repeat revascularization (TVR), and major adverse cardiac event (MACE) (death,
MI, TVR) rates of patients treated with drug-eluting stents.
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August 14, 2007:573–83 DES Thrombosis and Thrombus Burden in STEMIroups G0 to G3, and LTB, same as G4. The LTB group
ad higher in-hospital mortality (7.6% vs. 5.1%, p  0.18).
wo-year mortality and MACE rate were increased in LTB
atients compared with the STB patients (Figs. 3C and
D). The difference in mortality became evident early, at 30
ays (Fig. 4A), and there was no difference beyond 30 days
etween the 2 groups (Fig. 4B). An LTB was an indepen-
ent predictor of 30-day mortality (hazard ratio 1.96, 95%
onfidence interval 1.12 to 3.43, p  0.019), as well as
-year mortality and MACE (Table 3).
rocedural outcome. There were 7 (0.9%) procedural
eaths (procedural mortality: LTB group 1.8% vs. STB
roup 0.5%, p  0.1). Patients with LTB had a worse final
IMI flow grade, myocardial blush, and complete thrombus
emoval, as well as more cases of no reflow and distal
mbolization compared with STB patients (Table 4).
ncidence and predictors of stent thrombosis. Two-year
umulative stent thrombosis, IRA-ST (Fig. 5), and non–
RA-ST rates were 3.8  0.7% (26 events), 3.2  0.7% (22
vents), and 0.6  0.3% (4 events), respectively.
RA-ST. The 2-year cumulative IRA-ST rate was signif-
cantly higher in LTB (16 events) compared with STB (6
vents) patients (Fig. 5). An LTB was the most hazardous
ndependent predictor of IRA-ST (Table 5). The LTB
atients treated with RT had a lower 2-year cumulative
RA-ST (0% vs. 11.3%, p  0.001) compared with LTB
Figure 3 Mortality and MACE According to Thrombus Burden
Two-year cumulative mortality and MACE (death, repeat nonfatal myocardial infarct
thrombus grades before (A, B) and after stratification in large thrombus burden (Latients without RT. tIn relation to antiplatelet medication, 9 (40.9%) IRA-
Ts occurred under dual antiplatelet therapy, 4 (18.2%)
hortly (30 days) and 9 (40.9%) long (30 days) after
lopidogrel discontinuation. Chronologically, 4 (18.2%) pa-
ients had acute, 5 (22.7%) subacute, 2 (9.1%) late, and 11
50%) very late IRA-ST. There were 3 additional events
eyond the 2 years at 884, 1,067, and 1,074 days; 2 of them
ith LTB at baseline procedure.
There was no difference in the 2-year cumulative
RA-ST rate between PES and SES both for the total
opulation (PES 3.7  0.9% [18 events] vs. SES 2.1 
.06% [4 events], p  0.314) and the LTB group (PES
.5  2.1% [12 events] vs. SES 10.5  4.9% [4 events],
 0.598).
In patients presenting with stent thrombosis at the index
rocedure, the 2-year cumulative IRA-ST rate was 20.5 
.2% (4 events), all with LTB. Stent thrombosis at presen-
ation was an independent predictor of IRA-ST (Table 5).
mpact of IRA-ST on clinical outcome. Of the 22
RA-ST patients, 4 (18.2%) presented with unstable angina,
6 (72.7%) suffered a nonfatal repeat MI, and there were 2
9.1%) deaths; all underwent TLR. Two-year cumulative
ortality attributable to IRA-ST was only 0.3%.
The LTB patients had increased 2-year cumulative repeat
I (Fig. 6A) and TLR (Fig. 6C) rates compared with STB
atients. The 2-year cumulative repeat MI rate attributable
infarct-related artery repeat revascularization) rates according to the reclassified
d small thrombus burden (STB) (C, D). Other abbreviations as in Figure 2.ion, or
TB) ano IRA-ST (2.4%, 16 events) accounted for 40.7% of the
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DES Thrombosis and Thrombus Burden in STEMI August 14, 2007:573–83otal 2-year cumulative repeat MI rate (5.9%, 36 events).
he 2-year cumulative TLR rate attributable to IRA-ST
3.2%, 22 events) accounted for 67.3% of the total 2-year
umulative TLR rate (4.9%, 34 events). After excluding
atients with IRA-ST, there was no significant difference
etween LTB and STB patients in the 2-year cumulative
epeat MI and TLR rates (Figs. 6B and 6D).
The LTB patients had a worse 2-year and post-30-days
umulative MACE rate compared with STB patients
Figs. 7A and 7B). The 2-year cumulative MACE rate
ttributable to IRA-ST (3.2%, 22 events) accounted for
7.7% of the total 2-year cumulative MACE rate (18.1%,
32 events). The post-30-days cumulative MACE rate
ttributable to IRA-ST (1.2%, 13 events) accounted for
1.9% of the total post-30-days cumulative MACE rate
9.6%, 58 events). After excluding patients with IRA-ST,
Figure 4 Impact of Thrombus Burden on Mortality
Two-year (A) and post-30-days cumulative mortality (B) according to the pres-
ence of large thrombus burden (LTB) or small thrombus burden (STB) at the
index procedure.here was no significant difference in the post-30-days tumulative MACE rate between LTB and STB patients
Fig. 7C). The LTB patients treated with RT had a lower
ACE rate compared with LTB patients without RT
10.7% vs. 30% at 2 years, p  0.006) but similar to that of
TB patients (10.7% vs. 15.3% at 2 years, p  0.5).
iscussion
e report our experience on a large cohort of consecutive
atients presenting with STEMI and treated with PCI and
ES. This is the first report accounting for thrombus
urden. An LTB is a fundamental factor for adverse clinical
utcomes because it is related to increased 30-day mortality
nd very high rates of IRA-ST, which account for the
ajority of the post-30-days MACE.
hrombus burden. Almost 60% of the patients with
TEMI presented with an occluded IRA (G5). This is
ssentially a flow classification (TIMI flow grade 0), and
onsequently excludes these patients from any analysis
ocusing on thrombus burden. We propose a method that
llows thrombus burden estimation in almost 99% of these
atients after flow restoration with minimal intervention.
inimal antegrade flow (even TIMI flow grade 1) allowing
ontrast penetration beyond the occlusion is adequate to
llow thrombus evaluation.
There was no difference in the clinical outcome of
atients with thrombus G1 to G3, both in the univariate
nd the multivariate analysis. This was the rationale for
tratifying these groups as a single category defined as STB.
atients with no thrombus (G0) at presentation showed
orse outcomes compared with G1 to G3 patients and
imilar outcomes compared with G4 patients. Despite their
ncreased risk, these patients were included in the STB
roup because it is obvious that therapeutic strategies to
mprove their clinical outcome should not target thrombus.
ncidence of stent thrombosis during STEMI. Random-
zed trials of elective BMS implantation using dual anti-
latelet therapy reported stent thrombosis rates of 0.4% to
.3% (28,29). Stent thrombosis rates were reported to be
imilar (around 0.6%) between BMS and DES in a meta-
nalysis of 10 randomized trials of elective angioplasty (30).
oncerns were recently raised that DES might be more
hrombogenic compared with BMS in the long-term, espe-
ially when implanted in more complex patient subsets (31).
Acute coronary syndromes have been associated with
ncreased rates of stent thrombosis. In registries represent-
ng “real world” practice, which included patients with acute
oronary syndromes and STEMI treated either with BMS
16,17) or DES (18,32,33), higher rates of stent thrombosis
1.2% to 1.9%) were reported. In 4,607 patients treated with
MS for acute coronary syndromes, an even higher rate of
.9% of stent thrombosis was observed (15). In the
YPHOON (Trial to Assess the Use of the Cypher Stent
n Acute Myocardial Infarction Treated With Angioplasty)
rial, which randomized STEMI patients to SES or BMS,
he nonangiographic stent thrombosis was 3.4% and 3.6%,
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.4%, respectively, at 1 year (10). Similarly, in the SESAMI
Sirolimus-Eluting Stent Versus Bare-Metal Stent In Acute
ndependent Predictors of Clinical Outcomes
Table 3 Independent Predictors of Clinical Outcomes
Outcome Variable
2-yr mortality* Age (per 10-yr increase)
Cardiogenic shock
Prehospital resuscitation
Infarct-related artery
Right coronary artery (reference)
Left anterior descending coronary art
Circumflex coronary artery
Left main coronary artery
Graft
Large thrombus burden
Thrombus burden‡
Grade 4 (reference)
Grade 3
Grade 2
Grade 1
Grade 0
2-yr major adverse cardiac event† Age (per 10-yr increase)
Female
Cardiogenic shock
Stent thrombosis presentation (at index
Bifurcational stenting
Prehospital resuscitation
Rheolytic thrombectomy
Large thrombus burden
Thrombus burden‡
Grade 4 (reference)
Grade 3
Grade 2
Grade 1
Grade 0
Additional variables entered in the multivariate model but not found to be significant were: fe
ntervention, intra-aortic balloon pump, glycoprotein IIb/IIIa antagonists, bifurcational stenting, dir
ntered in the multivariate model but not found to be significant were: hypercholesterolemia, previ
isease, multivessel percutaneous coronary intervention, intra-aortic balloon pump, glycoprotein II
Similar results in the multivariate analysis (data not provided for the other predictors) were also sh
, grade 4) instead of 2 (large and small).
rocedural Outcome
Table 4 Procedural Outcome
Outcome
Total
(n  792)
STB
(n  567)
LTB
(n  225) p Value*
Final Thrombolysis In
Myocardial Infarction
flow grade 3
726 (91.7) 538 (94.9) 188 (83.6) 0.001
Myocardial blush
grade 3†
290 (47.6) 222 (53.2) 68 (35.4) 0.001
Complete thrombus
removal
757 (95.6) 556 (98.1) 201 (89.3) 0.001
No reflow 12 (1.5) 3 (0.5) 9 (4.0) 0.001
Distal embolization 59 (7.4) 20 (3.5) 39 (17.3) 0.001
ata are presented as n (%). *Small thrombus burden (STB) versus large thrombus burden (LTB)
roup. †Myocardial blush assessment was achieved in 609 patients (417 in the STB and 192 in the
TB group).yocardial Infarction) trial, 1-year stent thrombosis rates
ere 3.1% and 3.7% for SES and BMS, respectively (9).
We observed an incidence of angiographically docu-
ented stent thrombosis of 3.2% at 2 years. The angio-
raphically documented stent thrombosis underestimates
he true incidence of stent thrombosis because sudden
eaths and repeat MIs also may be related to this compli-
ation. Moreover, patients continued to present with stent
hrombosis beyond the 2-year time window. Similar cases of
ery late DES thrombosis in STEMI patients recently have
een reported (34,35).
echanisms of early and late stent thrombosis during
TEMI. Stent underexpansion, malapposition, residual
issections, and inflow/outflow disease have been well
stablished by intravascular ultrasound as mechanical causes
elated to early stent thrombosis for BMS (16,36–39) and
ES (40).
Hazard Ratio 95% Confidence Interval p Value
1.76 1.4–2.22 0.001
9.47 5.87–15.28 0.001
4.28 1.99–9.2 0.001
0.024
1.00
1.66 0.97–2.82 0.064
2.07 0.94–4.55 0.069
4.06 1.64–10.03 0.002
3.9 0.51–29.76 0.189
1.76 1.08–2.87 0.023
0.168
1.00
0.51 0.25–1.05 0.066
0.62 0.34–1.16 0.135
0.47 0.23–0.95 0.034
0.78 0.35–1.73 0.543
1.19 1.01–1.4 0.036
1.68 1.13–2.48 0.01
6.31 4.28–9.28 0.001
dure) 3.95 1.95–7.98 0.001
2.24 1.33–3.77 0.002
2.84 1.46–5.52 0.002
0.37 0.17–0.78 0.009
1.88 1.3–2.72 0.001
0.005
1.00
0.5 0.29–0.88 0.016
0.45 0.27–0.73 0.001
0.52 0.31–0.87 0.014
0.91 0.5–1.66 0.755
ender, hypercholesterolemia, smoking, multivessel disease, multivessel percutaneous coronary
ting, final Thrombolysis In Myocardial Infarction flow grade, and stent type. †Additional variables
cardial infarction, previous percutaneous coronary intervention, infarct-related artery, multivessel
ntagonists, direct stenting, final Thrombolysis In Myocardial Infarction flow grade, and stent type.
en thrombus burden was inserted as a variable with 5 categories (grade 0, grade 1, grade 2, gradeery
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DES Thrombosis and Thrombus Burden in STEMI August 14, 2007:573–83Primary stenting during acute MI has been recognized as
n independent predictor of late stent malapposition both
fter BMS (41) and DES (42) with an incidence 2- to
-fold higher compared with elective stenting. Thrombus
ompression/displacement by the stent struts in the acute
hase with abluminal thrombus resolution in the long term
as been proposed as a potential mechanism. However, its
ncidence with DES was 31.8%, 3 times higher compared
ith BMS (11.5%). These intravascular ultrasound obser-
ations may well explain the negative late loss observed in
TEMI trials with DES implantation and angiographic
ollow-up (3,6). An LTB was the strongest predictor of
tent thrombosis, and LTB patients experienced an ex-
remely high IRA-ST rate of 8.2%. It is rational that the
arger the thrombotic burden, the higher will be the inci-
ence of incomplete stent apposition that might account for
he higher rates of late stent thrombosis in LTB patients in
he long term. Moreover, the presence of thrombus has been
learly identified as a factor predisposing to stent thrombosis
14,36,39). Persistence of thrombus was an independent
redictor of early repeat MI in the PAMI (Primary Angio-
lasty in Myocardial Infarction) trials (43). Patients with
TB had an IRA-ST rate of 1.3%, similar to that reported
uring elective stenting (14,28,29).
Mechanical reasons may be inadequate to explain the
tent thrombosis rates during STEMI; their incidence is
ommon but the incidence of stent thrombosis remains
elatively low. Increased platelet activity and aspirin resis-
ance have been shown during STEMI (44). Furthermore,
tent thrombosis has been associated with an impaired
esponse to antiplatelet therapy, particularly in ACS pa-
Figure 5 Infarct-Related Artery Stent Thrombosis
Two-year cumulative infarct-related artery stent thrombosis (IRA-ST) rate for the
total population and according to the existence of large thrombus burden (LTB)
or small thrombus burden (STB) at the index procedure.ients (45). There is evidence that preintervention plaque
d
aomposition resembling that of a STEMI setting predis-
oses to stent thrombosis (46).
rocedural and periprocedural factors related to stent
hrombosis. Discontinuation of dual antiplatelet therapy
fter DES implantation has been related to an increased risk
or stent thrombosis (32,33). In our study, 59% of our
atients experienced IRA-ST while on aspirin mono-
herapy; 18% within the first 30 days after discontinuation
f clopidogrel. Stent thrombosis occurred in patients while
table for very long on antiplatelet monotherapy. Dual
ntiplatelet therapy was not able to prevent 41% of the
vents. Whether it would have prevented the late cases of
tent thrombosis remains unclear. The efficacy of dual
ntiplatelet therapy and its duration remains unclear in a
TEMI setting.
Bifurcation stenting has been recognized previously as a
isk factor for stent thrombosis in stable patients treated
ith DES (18,32). It was the second strongest independent
redictor of stent thrombosis in our study, and therefore it
hould be avoided if not absolutely necessary.
The worse procedural outcomes observed in LTB com-
ared with STB patients were translated into increased
hort-term mortality. Mortality after 30 days was compara-
le between the 2 groups. Similar results were recently
eported in a large cohort of patients (47).
The use of thrombectomy devices during STEMI re-
ains controversial. There were positive results reported
hen surrogate markers, such as ST-segment resolution,
IMI flow, or left ventricular remodeling (48–50), were
sed as end points, but there are no randomized studies
eporting positive outcomes in hard clinical end points such
s survival and MACE (23,24). The majority of these trials
ere underpowered for clinical outcomes, a fact that is
ndicative of the relative paucity of evidence, and thrombus
urden was not considered. Safety issues were recently
aised regarding routine application of thrombectomy in all
omers with STEMI (24). Based on the current results, the
otential of thrombectomy devices in STEMI should be
xplored selectively in patients at higher risk, such as those
ith LTB, in a prospective randomized fashion.
fficacy of DES and thrombus burden. The rate of TVR
ith BMS implantation for STEMI has been reported to be
% to 10% (51–53). Experience with DES for STEMI
ndependent Predictors offarct-Rela ed Artery Stent Thrombosis
Table 5 Independent Predictors ofInfarct-Related Artery Stent Thrombosis
Variable* Hazard Ratio
95% Confidence
Interval p Value
Age (per 10-yr increase) 0.55 0.37–0.82 0.003
Stent thrombosis at
presentation
6.24 2.06–18.92 0.001
Bifurcational stenting 4.06 1.64–10.02 0.002
Rheolytic thrombectomy 0.11 0.01–0.81 0.03
Large thrombus burden 8.73 3.39–22.47 0.001
Additional variables entered in the multivariate model but not found to be significant were
iabetes mellitus, previous myocardial infarction, previous percutaneous coronary intervention,
nd direct stenting.
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August 14, 2007:573–83 DES Thrombosis and Thrombus Burden in STEMIhowed lower TLR rates, around 2% to 4% (3,4,7,8,11,12).
n our patients the 2-year TLR rate was 4.9%, and it was
ignificantly higher in LTB compared with STB patients. It
as been reported that thrombus can modulate stent-based
rug elution and significantly alter vessel wall drug levels
nd potentially efficacy (54). Such concerns do not seem to
e confirmed because excluding reintervention caused by
RA-ST, which is not related to restenosis, the overall TLR
ate was very low (1.7%) and was comparable in LTB and
TB patients.
tudy limitations. This is a retrospective analysis with all
f the limitations arising from such an approach. Potential
hrombus burden modification related to preprocedural
harmacotherapy cannot be excluded. Angiography has
nherent limitations for assessing thrombus burden, and
here is no gold standard method to be compared with.
owever, it is the imaging modality used for decision
aking during PCI for STEMI, and in that respect this
lassification is clinically relevant. The poor outcome of G0
atients is poorly understood and should be further ex-
lored. Established parameters related to clinical outcomes
uch as infarct duration and myocardial blush were not
vailable for all patients and were not included in the
ultivariate analysis model. No quantitative angiographic
nalysis was performed, and parameters such as lesion
Figure 6 Impact of Thrombus Burden and IRA-ST on Repeat MI
Two-year cumulative (A) repeat myocardial infarction (MI) and (C) infarct-related ar
(LTB) or small thrombus burden (STB) at the index procedure. The corresponding r
presented in (B) and (D), respectively. After excluding IRA-ST, the total 2-year cumharacteristics and stent length also were not accounted for. pDiscontinuation of antiplatelet medication is a well-
stablished risk factor for stent thrombosis. In our analysis,
he antiplatelet medication status of the patients who
eveloped stent thrombosis was well established, but no
eliable information was possible to be obtained for patients
ho did not experience stent thrombosis, and therefore this
arameter also was not included in the multivariate analysis.
f note, 6 months of double antiplatelet medication, the
aximum prescribed in our patients, is regarded as inade-
uate today. All patients who developed stent thrombosis
eyond 6 months were on aspirin monotherapy. We cur-
ently prescribe 12 months of double antiplatelet medication
n all STEMI patients treated with DES.
onclusions
n patients presenting with STEMI, minimal intervention
ith either guidewire crossing or a small (diameter 1.5 mm)
eflated balloon passage or predilation restores flow enough
o allow intracoronary thrombus estimation in angiographi-
ally occluded vessels. Thrombus stratification in LTB (2
essel diameters) and STB has prognostic value.
Patients with STEMI treated with PCI and DES expe-
ience a high 2-year rate (3.2%) of IRA-ST, which contin-
es to occur even beyond that time window. An LTB is a
TLR
sion repeat revascularization (TLR) rates in relation to large thrombus burden
fter excluding patients with infarct-related artery stent thrombosis (IRA-ST) are
repeat MI and TLR rates are 3.3% and 1.7%, respectively.and
tery le
ates a
ulativeredictor of MACE. This is because of increased 30-day
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ates of early and late IRA-ST in LTB patients. An LTB
oes not influence the clinical antirestenotic efficacy of
ES.
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